Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Rigel Pharmaceuticals, Inc.'s quarterly P/E stands at 15.4x, up 115.2% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 82.1% YoY to 11.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 1.37 | 15.36 | 0.79 | 4.85 | 1.43 | 7.14 | 5.26 | 5.78 | — | — | 85.90 | — | — |
| — | +115.2% | -85.0% | -16.1% | — | — | -93.9% | — | — | — | +129.1% | — | — | |
| P/S Ratio | 1.67 | 2.26 | 2.89 | 1.95 | 0.84 | 1.53 | 1.31 | 1.29 | 0.98 | 2.19 | 1.77 | 1.67 | 2.08 |
| — | +47.7% | +120.1% | +51.3% | -14.6% | -30.2% | -25.7% | -22.9% | -53.0% | -0.1% | +39.8% | -26.5% | +27.7% | |
| P/B Ratio | 1.28 | 1.33 | 2.06 | 4.61 | 4.15 | 17.60 | 92.01 | — | — | — | — | — | — |
| — | -92.4% | -97.8% | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 6.51 | 48.84 | 9.17 | 5.65 | 2.78 | — | 5.22 | 3.29 | 450.79 | — | — | — | 9.44 |
| — | — | +75.6% | +71.5% | -99.4% | — | — | — | +4675.8% | — | — | — | — | |
| EV / EBITDA | 3.95 | 11.65 | 8.62 | 4.78 | 1.41 | 6.40 | 4.43 | 5.01 | 39.75 | — | 31.07 | — | — |
| — | +82.1% | +94.6% | -4.6% | -96.5% | — | -85.7% | — | — | — | +6.3% | — | — | |
| EV / EBIT | 4.03 | — | 9.88 | 4.70 | 1.41 | 6.40 | 4.45 | 5.08 | 42.17 | — | 26.55 | — | — |
| — | — | +122.1% | -7.4% | -96.7% | — | -83.2% | — | — | — | -3.6% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Rigel Pharmaceuticals, Inc.'s operating margin was 20.2% in Q1 2026, down 13.0 pp QoQ and down 3.7 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 38.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.3% | 92.2% | 91.5% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 89.4% | 95.5% | 96.0% |
| — | +0.5% | +1.7% | +9.0% | +3.5% | -1.5% | +0.6% | -10.5% | -3.8% | -3.2% | -10.0% | -3.4% | -0.5% | |
| Operating Margin | 42.6% | 20.2% | 33.2% | 40.9% | 60.1% | 23.9% | 28.9% | 25.4% | 1.2% | -23.6% | 5.5% | -15.9% | -19.6% |
| — | -15.6% | +14.8% | +61.0% | +4852.6% | +201.5% | +426.5% | +260.1% | +106.2% | +51.7% | +35.5% | +80.7% | +54.9% | |
| Net Margin | 124.7% | 14.7% | 384.0% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | -2.8% | -27.9% | 2.1% | -20.2% | -24.5% |
| — | -31.4% | +1442.4% | +78.8% | +2196.9% | +176.9% | +1109.2% | +211.0% | +88.6% | +46.2% | -24.6% | +76.2% | +45.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 185.9% | 2.2% | 105.3% | 28.0% | 118.6% | 104.7% | 436.2% | — | — | — | — | — | — |
| — | -97.9% | -75.9% | — | — | — | — | — | — | — | — | — | — | |
| ROA | 108.3% | 1.7% | 70.9% | 12.4% | 31.2% | 6.7% | 9.5% | 9.3% | -0.8% | -6.8% | 0.6% | -4.9% | -5.5% |
| — | -74.8% | +650.0% | +33.9% | +3955.1% | +199.5% | +1391.6% | +289.4% | +85.3% | +35.5% | -43.5% | +68.7% | +43.7% | |
| ROIC | 45.8% | 2.2% | 6.5% | 19.4% | 74.2% | 47.4% | 6138.2% | — | — | -434.8% | — | — | — |
| — | -95.4% | -99.9% | — | — | +110.9% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Rigel Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 3.8x, up from 2.2x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 18.9% YoY to 2.62x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.11 | 0.14 | 0.52 | 0.75 | 3.29 | 18.24 | — | — | — | — | — | — |
| — | -96.5% | -99.3% | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.42 | 3.85 | 2.24 | 2.10 | 0.99 | 4.57 | 3.47 | 4.11 | 56.92 | — | 26.82 | — | — |
| — | -15.7% | -35.5% | -48.9% | -98.3% | — | -87.0% | — | — | — | +52.5% | — | — | |
| Current Ratio | 2.42 | 2.62 | 2.42 | 2.28 | 2.02 | 2.20 | 2.13 | 1.96 | 1.62 | 1.26 | 1.86 | 1.97 | 2.29 |
| — | +18.9% | +13.4% | +16.1% | +25.3% | +74.1% | +14.5% | -0.4% | -29.6% | -46.2% | +4.8% | -15.8% | +4.5% | |
| Quick Ratio | 2.30 | 2.48 | 2.30 | 2.06 | 1.90 | 2.13 | 2.04 | 1.87 | 1.48 | 1.17 | 1.76 | 1.84 | 2.05 |
| — | +16.7% | +13.0% | +9.9% | +28.9% | +81.5% | +15.9% | +1.6% | -27.8% | -44.3% | +7.5% | -15.7% | -1.6% | |
| Interest Coverage | 17.14 | 8.29 | 12.20 | 15.58 | 33.01 | 7.21 | 8.79 | 7.03 | 0.49 | -3.40 | 1.39 | -2.00 | -2.54 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying RIGL stock.
Rigel Pharmaceuticals, Inc.'s current P/E is 1.4x. The average P/E over the last 4 quarters is 5.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Rigel Pharmaceuticals, Inc.'s current operating margin is 42.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rigel Pharmaceuticals, Inc.'s business trajectory between earnings reports.